An Associate Professor of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center, Dr. Yarchoan is a physician-scientist and an emerging leader in cancer immunotherapy. He co-leads a multi-pronged strategy to attack FLC using a targeted therapeutic vaccine, immune cell therapy (“TCR-T”), and agents aimed at reversing an immune-suppressive tumor microenvironment. Promising results of the initial clinical trial of the FLC vaccine were published in the December 2025 issue of the high impact journal Nature Medicine.